体外受精-胚胎移植 中国就医指南

In Vitro Fertilization and Embryo Transfer (IVF-ET) is not a disease but an advanced assisted reproductive technology (ART) used to treat infertility in individuals and couples who cannot conceive naturally. IVF-ET involves ovarian stimulation, transvaginal oocyte retrieval, fertilization of eggs with sperm in a controlled laboratory environment (in vitro), embryo culture for 3–5 days, and subsequent transfer of one or more viable embryos into the uterine cavity. The procedure may be combined with intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), or frozen-thawed embryo transfer (FET) depending on clinical indications. Pathogenesis underlying the need for IVF-ET is multifactorial: female factors include tubal occlusion, severe endometriosis, diminished ovarian reserve, premature ovarian insufficiency, and ovulatory disorders; male factors encompass severe oligoasthenoteratozoospermia, obstructive azoospermia, or failed fertilization in prior cycles; unexplained infertility and genetic conditions also constitute key indications. Epidemiologically, infertility affects approximately 15–17% of reproductive-age couples globally, with IVF utilization rising steadily—China performs over 1 million ART cycles annually, representing one of the world’s largest and most rapidly expanding IVF markets. Risk factors associated with reduced IVF success include advanced maternal age (>35 years), obesity (BMI ≥30), smoking, excessive alcohol intake, chronic stress, polycystic ovary syndrome (PCOS), and prior uterine surgery. Psychosocial impact is profound: patients frequently experience anxiety, depression, marital strain, financial distress, and social stigma—studies report up to 40% of IVF patients meet criteria for clinical anxiety or depression during treatment. Quality of life declines significantly across physical, emotional, and social domains, particularly during ovarian stimulation and the two-week wait post-transfer. Despite high emotional burden, successful IVF-ET restores biological parenthood for many, improving long-term psychological well-being and relational satisfaction when pregnancy is achieved. However, multiple cycles may be required—cumulative live birth rates per initiated cycle range from ~40% in women under 35 to <5% in those over 44—underscoring the importance of realistic counseling, psychosocial support, and individualized protocols.

# 体外受精-胚胎移植（IVF-ET）治疗方案与费用明细（生殖医学科）

一、非手术/药物/监测方案

适用人群：卵巢功能正常、输卵管通畅、男方轻度少弱精、首次助孕者

• •基础促排卵+自然周期监测：B超+性激素6项+黄体支持，¥3,800–¥6,200
• •标准长方案（GnRH-a降调节）：含垂体降调、促排卵（rFSH/HMG）、扳机、黄体支持及全程B超/激素监测，¥12,500–¥18,000
• •拮抗剂方案（灵活高效）：适用于高反应或PCOS患者，含GnRH拮抗剂、个体化促排、内膜准备，¥14,200–¥20,500

二、手术/核心介入方案

适用人群：需取卵、胚胎移植、宫腔镜预处理者

• •经阴道超声引导下取卵术+胚胎培养+鲜胚移植（含实验室操作、胚胎评估、移植管置入）：¥28,000–¥36,000
• •冻融胚胎移植（FET）周期（含内膜准备、解冻、移植、黄体支持）：¥12,000–¥16,800
• •术前必查：染色体核型分析、AMH、传染病八项、宫腔镜检查（如异常）等，¥2,600–¥4,900

三、复杂/并发症/耐药方案

• •多次移植失败（RIF）：ERA子宫内膜容受性检测+免疫调节（如泼尼松/阿司匹林）+凝血功能干预，¥8,500–¥15,000
• •严重男性因素（TESE+ICSI）：显微取精+单精子卵胞浆内注射，¥42,000–¥53,000
• •PGT-A（胚胎植入前遗传学检测）：活检+高通量测序+报告解读，¥18,000–¥25,000/周期

四、方案快速选择指南

• •预算有限/初诊者 → 拮抗剂方案+鲜胚移植（约¥40,000全周期）
• •反复失败/高龄（≥38岁） → PGT-A+冻胚移植+FET优化内膜（约¥65,000–¥78,000）
• •严重少精/无精 → TESE+ICSI+PGT-A（约¥85,000–¥95,000）